文献速递造血干细胞移植与细胞治疗

芦可替尼治疗糖皮质激素难治性急性移植物抗宿主病的研发历程

The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease.
PubMed 文献 · Blood Adv · 2020-01-01

急性移植物抗宿主病(aGVHD)是异基因造血细胞移植后的致命并发症,糖皮质激素难治性患者预后极差。芦可替尼通过抑制JAK1/2阻断多种促炎细胞因子下游信号,近期一项多中心3期临床试验显示其疗效结局较最佳可用治疗显著改善,将带来治疗范式的转变。

要点

  • 糖皮质激素难治性aGVHD患者预后极差,异基因造血细胞移植后1年生存率低。
  • 芦可替尼抑制JAK1和JAK2,阻断多种促炎细胞因子受体的下游信号传导。
  • 多中心3期试验显示芦可替尼较最佳可用治疗在疗效结局上显著改善。

核心结论

  • 多中心3期临床试验显示芦可替尼较最佳可用治疗在疗效结局上显著改善,将带来糖皮质激素难治性aGVHD治疗的范式转变。

研究设计与样本

  • 原文为综述,未报告系统检索范围;文中提及一项多中心3期临床试验,未报告样本量。

主要发现

  • 糖皮质激素难治性aGVHD患者预后极差,异基因造血细胞移植后1年生存率低。
  • 芦可替尼抑制JAK1和JAK2,后者是多种细胞因子受体下游信号传导所必需。
  • 多中心3期临床试验显示芦可替尼较最佳可用治疗在疗效结局上显著改善。

临床怎么用

  • 原文未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute graft-versus-host disease (aGVHD) is a life-threatening complication after allogeneic hematopoietic cell transplantation (allo-HCT). Despite the use of prophylactic immunosuppression including calcineurin inhibitors, antimetabolites, antithymocyte globulin, or posttransplant cyclophosphamide, patients still develop severe aGVHD. In particular, patients with glucocorticoid-refractory GVHD (SR-GVHD) have a dismal prognosis with a low 1-year post-allo-HCT survival rate. Most classical drugs used to prevent or treat aGVHD target 1 specific pathway such as calcineurin inhibitors or mammalian target of rapamycin inhibitors, or they interfere with fast-dividing activated cells (eg, methotrexate, mycophenolate, and cyclophosphamide). In contrast to these drugs, inhibition-of-signaling molecules, used by multiple immune cells and critical for signal transduction of multiple proinflammatory cytokines, could be more efficacious at blocking GVHD. Ruxolitinib blocks Janus kinases 1 and 2, which are required to mediate the downstream signaling of multiple cytokine receptors. Recently, a multicenter phase 3 clinical trial showed that ruxolitinib led to significant improvements in efficacy outcomes compared to best available therapy, which will lead to a paradigm shift in the treatment of SR-GVHD.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Zeiser R, Socié G. The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. Blood Adv. 2020. PMID: 32780849. doi:10.1182/bloodadvances.2020002097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。